863288-34-0
CJC-1295 (no DAC)
Tetra-substituted GHRH(1-29) analogue without the drug affinity complex. Short-acting.
Typical release99.0%
From
£42.00
In stock
Growth Factor & Secretagogue
GHRP-6
Growth hormone releasing peptide 6 · SKF-110679
First-generation hexapeptide secretagogue at GHS-R1a, with characteristic off-target endocrine activity.
Total, ex VAT
£29.00
- Released at ≥ 98.0% (RP-HPLC, area %)
- Identity confirmed by ESI-MS against theoretical mass
- Batch certificate matched to the vial, verifiable online
- Same working day dispatch before 14:00, tracked
For laboratory research use only. Not for human or veterinary use, and not a medicine, food or cosmetic. Sold to qualified researchers and institutions who accept responsibility for safe handling and lawful use.
Compound data
What is in the vial
Indicative values for this line. The certificate issued with your batch is the authoritative record and reports the measured figures for the material you receive.
- CAS number
- 87616-84-0
- Molecular formula
- C46H56N12O6
- Average mass
- 873.01 g/mol
- Sequence
- His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
- Residues
- 6
- Class
- Ghrelin receptor (GHS-R1a) agonist
- Form as supplied
- Lyophilised powder
- Appearance
- White to off-white lyophilised powder
- Purity specification
- ≥ 98.0% (RP-HPLC, area %)
- Solubility
- Soluble in sterile or bacteriostatic water.
- Storage
- Lyophilised: −20 °C, desiccated and dark. Reconstituted: 2–8 °C.
Targets and pathways
- Growth hormone secretagogue receptor 1a (GHS-R1a)
Overview
About GHRP-6
GHRP-6 is the compound that opened the secretagogue field. A six-residue peptide with D-tryptophan and D-phenylalanine, it demonstrated that growth hormone release could be triggered through a receptor distinct from GHRHR — the receptor later identified as GHS-R1a, the ghrelin receptor.
It also raises cortisol and prolactin, which later analogues were designed to avoid. In research that is not necessarily a defect: holding GHRP-6 alongside ipamorelin gives a selective and a non-selective agonist at the same receptor, which is how off-target endocrine contributions are isolated.
In short
- The founding secretagogue peptide; led to identification of GHS-R1a
- Raises cortisol and prolactin alongside growth hormone
- Paired with ipamorelin to separate on- from off-target endocrine effects
- Released at ≥ 98.0% area-percent by RP-HPLC
Where it is used
Research applications
Receptor discovery history
The compound is a standard tool in work retracing the pharmacology that led to ghrelin's identification.
Appetite signalling
Strong GHS-R1a agonism makes it a common tool in feeding-behaviour models.
Selectivity comparison
Non-selective activity provides the contrast case against selective agonists at the same receptor.
Handling
Reconstitution and stability
Reconstitution
Reconstitute with sterile or bacteriostatic water added slowly against the inner wall of the vial. Allow the cake to dissolve without agitation, swirling gently if required. Do not vortex or shake.
Stability
Lyophilised at −20 °C, desiccated and protected from light, stable for at least 24 months. Reconstituted and held at 2–8 °C, use within 28 days. Avoid repeated freeze-thaw.
Notes
- Bring the vial to room temperature before opening so atmospheric moisture does not condense onto cold powder.
- Record the reconstitution date on the vial; concentration drift between runs is usually evaporation, not synthesis variance.
- Aliquot at first reconstitution where the working programme needs more than a few withdrawals.
Laboratory reference
Reconstitution calculator
Enter the fill weight on the vial and the diluent volume you intend to add. The calculator returns the resulting solution concentration and the volume that contains a given mass.
- Concentration
- 2.500 mg/mL · 2500 µg/mL
- Volume containing target mass
- 100.0 µL · 0.1000 mL
Figures are mass-to-volume arithmetic for laboratory preparation of GHRP-6 and take no account of net peptide content, which is stated on the batch certificate and should be applied to the fill weight before calculating. Nothing here constitutes dosing, administration or clinical guidance of any kind.
Published work
What the literature reports
Summaries of published findings, provided as research reference. These describe work done by others in preclinical and clinical settings; they are not claims about this material or outcomes for any reader.
Secretagogue characterisation
Original description of the hexapeptide's growth hormone releasing activity through a non-GHRH pathway.
Bowers et al., Endocrinology, 1984
Receptor identification
Cloning of the growth hormone secretagogue receptor, the target of GHRP-6 and later ghrelin.
Howard et al., Science, 1996
Questions
GHRP-6 — asked and answered
Something not covered here? Ask us directly — technical questions reach someone who runs the assays.
- Why stock a non-selective compound?
- Because the contrast is informative. Comparing GHRP-6 against a selective agonist at the same receptor is how the off-target endocrine contribution is measured.
- Does it contain D-amino acids?
- Yes, D-tryptophan and D-phenylalanine. Both are confirmed by mass on the certificate.
- Is it stable?
- Yes. Six residues, no methionine or cysteine, and C-terminally amidated. 28 days in solution at 2–8 °C.
Same class
Others in Growth Factor & Secretagogue
170851-70-4
Most orderedIpamorelin
Selective ghrelin receptor agonist pentapeptide with minimal cross-activity.
Typical release99.2%From
£34.00
In stock
86168-78-7
Sermorelin
The native GHRH(1-29) fragment, unmodified. The reference sequence for GHRH analogue work.
Typical release98.8%From
£52.00
In stock
218949-48-5
Tesamorelin
Full-length GHRH(1-44) with an N-terminal hexenoyl group for protease resistance.
Typical release98.6%From
£114.00
In stock
Important
GHRP-6 is supplied strictly for laboratory research and analytical use. It is not a medicine, food, cosmetic or veterinary product; it is not for human or animal consumption; and it is not intended to diagnose, treat, cure or prevent any condition. It is not manufactured, tested or released to any standard that would support administration to humans or animals. Information on this page is compiled for research reference and is not medical advice. No dosing, administration or therapeutic guidance is given or implied. By ordering you confirm you are a qualified researcher or institution and accept responsibility for safe handling and lawful use.